Pura Vida Investments’s Coherus Oncology CHRS Stock Holding History

Pura Vida Investments’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-400,000	Closed	-$8.1M	–	106
2019 Q3	$8.1M	Buy	+400,000	New	+$7.99M	1.38%	29
2018 Q2	–	Sell	-50,000	Closed	-$553K	–	98
2018 Q1	$553K	Hold	50,000	–	–	0.33%	59
2017 Q4	$440K	Buy	+50,000	New	+$535K	0.18%	65

Other funds holding CHRS

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Pura Vida Investments's CHRS Position: Q4 2019 in Review

Pura Vida Investments sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 50,000 shares — an estimated $1.01M sold.

Pura Vida Investments first reported a position in CHRS in Q4 2017 and held it in 5 quarters. The position peaked at $2.41M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

Pura Vida Investments reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
Pura Vida Investments sold 50,000 Coherus Oncology shares in Q4 2019, an estimated $1.01M.
Pura Vida Investments first reported a position in Coherus Oncology in Q4 2017 and held it in 5 quarters.
Pura Vida Investments's Coherus Oncology position peaked at $2.41M in Q2 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.